Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Approval Delay For Green Cross But Long Term Strategy Intact

Executive Summary

Green Cross has hit a bump in its journey to commercialize an immunoglobulin product in the US, but analysts say the approval delay will not be a significant obstacle to its longer term North American strategy.

You may also be interested in...



GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy

Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.

Interview: GC Pharma Begins New Chapter For Globalization

GC Pharma, formerly known as Green Cross Corp., is set to move on to the next stage of its ongoing globalization scheme with the completion of a biomanufacturing facility in Canada. Joon Soo Ryu, its vice president of office of corporate strategy, talks to Scrip about the leading Korean pharma’s North American strategy, including how it is approaching the market differently versus its Korean peers.

Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross

The latest drug development news and highlights from our FDA Performance Tracker

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel